One of the most exciting bits of news that the COVID-19 pandemic has provided in the clinical research arena is demonstrating that adaptive, platform randomized controlled trials (ad-RCTs) provided useful responses about clinical efficacy and safety of medicines in reasonable time frames. Among others, four of these ad-RCTs (Discovery [1], RECOVERY [2], REMAP-CAP [3], Solidarity [4]), have shown that some of the trial antiviral therapies were efficacious in the treatment of hospitalized COVID-19 patients compared to control groups receiving the standard of care.
